"Losartan" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
An antagonist of ANGIOTENSIN TYPE 1 RECEPTOR with antihypertensive activity due to the reduced pressor effect of ANGIOTENSIN II.
| Descriptor ID |
D019808
|
| MeSH Number(s) |
D02.455.426.559.389.185.475 D03.383.129.308.507 D03.383.129.617.467
|
| Concept/Terms |
Losartan- Losartan
- 2-Butyl-4-chloro-1-((2'-(1H-etrazol-5-yl) (1,1'-biphenyl)-4-yl)methyl)-1H-imidazole-5-methanol
Losartan Potassium- Losartan Potassium
- Potassium, Losartan
- Losartan Monopotassium Salt
- Monopotassium Salt, Losartan
- Salt, Losartan Monopotassium
|
Below are MeSH descriptors whose meaning is more general than "Losartan".
Below are MeSH descriptors whose meaning is more specific than "Losartan".
This graph shows the total number of publications written about "Losartan" by people in this website by year, and whether "Losartan" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2014 | 0 | 2 | 2 |
| 2019 | 1 | 0 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Losartan" by people in Profiles.
-
Total Neoadjuvant Therapy With FOLFIRINOX in Combination With Losartan Followed by Chemoradiotherapy for Locally Advanced Pancreatic Cancer: A Phase 2 Clinical Trial. JAMA Oncol. 2019 Jul 01; 5(7):1020-1027.
-
Prevalence of angiotensin II type 1 receptor (AT1R)-activating autoantibodies in primary aldosteronism. J Am Soc Hypertens. 2015 Jan; 9(1):15-20.
-
Autoimmune mechanisms activating the angiotensin AT1 receptor in 'primary' aldosteronism. J Clin Endocrinol Metab. 2014 May; 99(5):1790-7.
-
AT1 receptor ligands: virtual-screening-based design with TOPP descriptors, synthesis, and biological evaluation of pyrrolidine derivatives. ChemMedChem. 2007 Sep; 2(9):1298-310.